Surgery Partners (SGRY) files Form 144 for 150,000-share sale via UBS
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- Planned sale of 150,000 shares with an aggregate market value of $3,294,454.97 filed for sale on 09/18/2025 through UBS.
- Multiple recent insider sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including two transactions of 100,000 shares, indicating substantial insider disposition activity.
Insights
TL;DR: Significant insider selling reported; timing aligns with option exercise and immediate sale through UBS.
The filing shows an insider exercising equity compensation and proposing an immediate sale of 150,000 common shares valued at about $3.29 million. Prior transactions by Wayne DeVeydt between late August and mid-September 2025 document repeated disposals of company stock, including two large 100,000-share transactions. From a trading-flow perspective, this pattern reflects exercise-and-sell activity rather than a single isolated sale; investors should note the volume but the filing does not state any nonpublic adverse information or change in company operations.
TL;DR: Recurrent insider sales and same-day exercise-and-sell warrant governance attention.
The report evidences equity option exercise on 09/18/2025 followed by a proposed sale the same day, and a series of recent dispositions by an individual (Wayne DeVeydt). While such behavior is common with option liquidity, repeated large sales can raise questions about insider alignment with shareholders. The filing, however, contains the standard attestation that no material undisclosed information is known to the seller; no further governance disclosures are provided within this form.